secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-07-14T12:30:27+00:00
Accession:  0001193125-26-302608
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax unveils SNDX-4321 (allosteric EGFRi) and SNDX-62122 (menin inhibitor) at R&D event
--------------------------------------------------------------------------------

- SNDX-4321: novel mutant-selective allosteric EGFR inhibitor for NSCLC; IND expected by end of 2026, Phase 1 in 2027.
- SNDX-62122: first next-gen menin inhibitor from internal library; IND and Phase 1 in MF expected in 2027.
- Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26.
- Revumenib Phase 1/2 trial in MF expected to initiate in 4Q26 with initial data in H2 2027.
- Company highlights late-stage revumenib and axatilimab programs in acute leukemia and chronic GVHD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/0001193125-26-302608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/sndx-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-302608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer